GlassScriptPhysician profile
Noel H Stallmann
NPI 1962858928
$4,459.46
in general payments reported to CMS, 2019-2025
23 companies · $923 in 2025
The $923 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $927 · 2022: $396 · 2023: $1,436 · 2024: $778 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,929 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,929.19 |
| Education | $207.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $874.84 | 2021-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $632.80 | 2021-2025 | Veozah |
| Abbvie INC. | $586.50 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $508.32 | 2022-2024 | Farxiga, Breztri, Fasenra |
| Esperion Therapeutics, INC. | $490.15 | 2021-2023 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $292.11 | 2025 | |
| Silk Road Medical, INC. | $178.18 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Mylan Specialty L.P. | $118.78 | 2022-2023 | Yupelri |
| Novo Nordisk INC | $111.60 | 2023-2025 | Ozempic, Rybelsus |
| Teleflex LLC | $111.04 | 2024 | Urolift |
| Novartis Pharmaceuticals Corporation | $95.94 | 2022-2023 | |
| Scpharmaceuticals INC. | $95.76 | 2025 | |
| Edwards Lifesciences Corporation | $80.70 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $48.66 | 2021 | |
| Idorsia Pharmaceuticals US INC | $46.79 | 2023 | Quviviq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $45.00 | 2025 | |
| Supernus Pharmaceuticals, INC. | $38.14 | 2024 | Qelbree |
| Phathom Pharmaceuticals, INC. | $20.35 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $20.14 | 2023 | Trelegy Ellipta |
| Dexcom, INC. | $18.80 | 2023 | Dexcom G6 Transmitter |
| Bausch Health US, LLC | $17.89 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.20 | 2022 | |
| Collegium Pharmaceutical, INC. | $12.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noel Stallmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.